natgillin/translations-raw huggingface dataset:
• Reumatoid artrit: Leflunomidbehandling indledes sædvanligvis med en startdosis på 100 mg en gang daglig i 3 dage.
• In rheumatoid arthritis: leflunomide therapy is usually started with a loading dose of 100 mg once daily for 3 days.
Såfremt patienten i forvejen behandles med NSAID og/eller kortikosteroider, kan der fortsættes hermed efter påbegyndt behandling med leflunomid.
If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, these may be continued after starting leflunomide.
6), eller hvis du er allergisk over for teriflunomid (til behandling af multipel sklerose), - hvis du har leverproblemer, - hvis du har har moderate til svære nyreproblemer, - hvis du har et alvorligt lavt antal proteiner i dit blod (hypoproteinæmi), - hvis du lider af en sygdom der påvirker dit immunforsvar (f.eks. aids) - hvis du har problemer med din knoglemarv, eller hvis du har et lavt antal røde eller hvide blodlegemer, eller et reduceret antal blodplader, - hvis du lider af en alvorlig infektion, - hvis du er gravid, tror du er gravid eller ammer.
often accompanied by fever, joint pain, red skin stains, or blisters e.g. Stevens-Johnson syndrome) or to any of the other ingredients of this medicine (listed in section 6), or if you are allergic to teriflunomide (used to treat multiple sclerosis), - if you have any liver problems, - if you have moderate to severe kidney problems, - if you have severely low numbers of proteins in your blood (hypoproteinaemia), - if you suffer from any problem which affects your immune system (e.g. AIDS), - if you have any problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets, - if you are suffering from a serious infection, - if you are pregnant, think you may be pregnant, or are breast-feeding.
Luftvejsreaktioner
Respiratory reactions
30 filmovertrukne tabletter 100 filmovertrukne tabletter
30 film-coated tablets 100 film-coated tablets
LÆGEMIDDELFORM OG ANTAL (PAKNINGSSTØRRELSE)
PHARMACEUTICAL FORM AND CONTENTS
Behandlingsvarigheden var 6 måneder.
The treatment duration was 6 months.
• Arthritis psoriatica: Leflunomidbehandling indledes med en startdosis på 100 mg en gang daglig i 3 dage.
• In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
Risikoen for interstitiel lungesygdom og pulmonal hypertension kan være øget hos patienter med interstitiel lungesygdom i anamnesen.
The risk of their occurrence can be increased in patients with a history of interstitial lung disease.
Gem indlægssedlen.
- Keep this leaflet.
Gullig til okkerfarvet trekantet filmovertrukken tablet, præget med ZBO på den ene side.
Yellowish to ochre and triangular film-coated tablet, imprinted with ZBO on one side.
pancytopeni skal Leflunomid Zentiva og anden samtidig behandling med myelosuppresive lægemidler seponeres og leflunomid udvaskningsproceduren påbegyndes.
In case of severe haematological reactions, including pancytopenia, Leflunomide Zentiva and any concomitant myelosuppressive treatment must be discontinued and a leflunomide washout procedure initiated.
I forsøg med gentagen dosering til patienter med reumatoid artrit er de farmakokinetiske parametre for A771726 lineære i doseringsintervallet 5-25 mg. I disse forsøg hænger den kliniske effekt tæt sammen med plasmakoncentrationen af A771726 og den daglige dosis af leflunomid.
In multiple dose studies in patients with rheumatoid arthritis, the pharmacokinetic parameters of A771726 were linear over the dose range of 5 to 25 mg.
Alle patienter fik folininsyre 1 mg 2 gange daglig.
All patients received folate 1 mg bid.
De hyppigst rapporterede bivirkninger ved behandling med leflunomid er: let blodtryksstigning, leukopeni, paræstesi, hovedpine, svimmelhed, diarré, kvalme, opkastning, gener fra mundslimhinden, (f.eks. aftøs stomatitis, mundsår), abdominalsmerter, øget hårtab, eksem, udslæt (inklusive makulopapuløst udslæt), pruritus, tør hud, seneskedehindebetændelse, øget kreatinkinase, anoreksi, vægttab (sædvanligvis ubetydeligt), asteni, milde allergiske reaktioner og stigning i leverparametre (transaminaser særligt ALAT), mindre hyppigt gamma-GT, basisk fosfatase og bilirubin).
The most frequently reported adverse effects with leflunomide are: mild increase in blood pressure, leucopenia, paraesthesia, headache, dizziness, diarrhoea, nausea, vomiting, oral mucosal disorders (e.g. aphthous stomatitis, mouth ulceration), abdominal pain, increased hair loss, eczema, rash (including maculo-papular rash), pruritus, dry skin, tenosynovitis, CPK increased, anorexia, weight loss (usually insignificant), asthenia, mild allergic reactions and elevation of liver parameters (transaminases (especially ALT), less often gamma-GT, alkaline phosphatise, bilirubin)).
- et mindre fald i antallet af hvide blodlegemer (leukopeni), - lette allergiske reaktioner, - appetitløshed, vægttab (sædvanligvis ubetydeligt), - slaphed (asteni), - hovedpine, svimmelhed, - unormale hudfornemmelser såsom prikken (paræstesi), - let forhøjelse af blodtrykket, - colitis
- a slight decrease in the number of white blood cells (leucopenia), - mild allergic reactions, - loss of appetite, weight loss (usually insignificant), - tiredness (asthenia), - headache, dizziness, - abnormal skin sensations like tingling (paraesthesia), - mild increase in blood pressure,
Efter 16 ugers behandling var forskellen i responsraterne statistisk signifikant til methotrexats fordel til børnegigt ”definition of improvement (DOI)” ≥30 % (p=0,02 %).
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg. After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥30% (p=0.02).
Er du i tvivl, så spørg lægen eller på apoteket.
- If you have any further questions, ask your doctor, pharmacist or nurse.
Endvidere kan det at skifte fra leflunomid til et andet DMARD uden at følge udvaskningsproceduren (se pkt.
Moreover, switching from leflunomide to another DMARD without following the washout procedure (see section 4.4) may also increase the risk of serious adverse reactions even for a long time after the switching.
Meget sjældne bivirkninger (kan påvirke op til 1 ud af 10.000 personer)
Very rare side effects (may affect up to 1 in 10,000 people)
For at sikre, at fosteret ikke udsættes for toksiske koncentrationer af A771726 (fokuskoncentration under 0,02 mg/l) anbefales en af følgende procedurer til kvinder i leflunomidbehandling, som ønsker at blive gravide:
For women receiving leflunomide treatment and who wish to become pregnant, one of the following procedures is recommended in order to ascertain that the foetus is not exposed to toxic concentrations of A771726 (target concentration below 0.02 mg/L):
Efter ophør med leflunomidbehandling administreres:
After stopping treatment with leflunomide:
Leverreaktioner
Liver reactions
Sådan skal du tage Leflunomid Zentiva
How to take Leflunomide Zentiva
Hjælpestof, som behandleren skal være opmærksom på Hver tablet indeholder 78 mg lactosemonohydrat.
Excipients with known effect Each tablet contains 78 mg of lactose monohydrate.
Leflunomid Zentiva 20 mg filmovertrukne tabletter er gullige til okkerfarvede og trekantede Præget med ZBO på den ene side.
Leflunomide Zentiva 20 mg film-coated tablets are yellowish to ochre and triangular.
Præget med ZBP på den ene side.
Imprint on one side: ZBP
MÆRKNING DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON, BLISTER PAKNING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER PACKAGING/BLISTER PACK
Hjælpestof som behandleren skal være opmærksom på Hver tablet indeholder 72 mg lactosemonohydrat.
Excipients with known effect Each tablet contains 72 mg of lactose monohydrate.
Det skal du vide, før du begynder at tage Leflunomid Zentiva Sådan skal du tage Leflunomid Zentiva Bivirkninger
What Leflunomide Zentiva is and what it is used for What you need to know before you take Leflunomide Zentiva How to take Leflunomide Zentiva Possible side effects
I fase III forsøgene var ACR-responsraterne for leflunomid 20 mg daglig versus placebo 54,6% versus 28,6% (forsøg MN301) og 49,4% versus 26,3% (forsøg US301).
In the phase III trials, the ACR response rates for leflunomide 20 mg/day versus placebo were 54.6% versus 28.6% (study MN301), and 49.4% versus 26.3% (study US301).After 12 months with active treatment, the ACR response rates in leflunomide patients were 52.3% (studies MN301/303), 50.5% (study MN302) and 49.4% (study US301), compared to 53.8% (studies
Leflunomid kan tages i forbindelse med et måltid, idet absorptionen er uændret, hvad enten patienten er fastende eller ej. På grund af den lange halveringstid af A771726 (ca. 2 uger), blev der i kliniske forsøg givet en initialdosis på 100 mg i 3 dage for at opnå hurtig steady-state koncentrationer af A771726.
Due to the very long half-life of A771726 (approximately 2 weeks), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state levels of A771726.
Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000 personer)
Rare side effects (may affect up to 1 in 1,000 people)
Ved behandling med leflunomid er beskrevet colitis, herunder mikroskopisk colitis.
Colitis, including microscopic colitis has been reported in patients treated with leflunomide.
- Aktivt stof: Leflunomid.
- The active substance is leflunomide.
Povidon (E 1201) Crospovidon, (E 1202) Kolloid vandfri silica Magnesiumstearat (E 470b) Lactosemonohydrat
Povidone (E1201) Crospovidone (E1202) Silica colloidal anhydrous Magnesium stearate (E470b) Lactose monohydrate
Dog har doseringen til lette individer resulteret i en relativ lav eksponering over for leflunomid (se pkt.
The pattern of adverse events of leflunomide and methotrexate seems to be similar, but the dose used in lighter subjects resulted in a relatively low exposure (see section 5.2).
Kontakt din læge for yderligere information om blodprøverne.
For further information on the laboratory testing please contact your doctor.
Indlægsseddel: Information til brugeren Leflunomid Zentiva 100 mg filmovertrukne tabletter leflunomid
Package leaflet: Information for the user Leflunomide Zentiva 100 mg film-coated tablets leflunomide
Indlægsseddel: Information til brugeren Leflunomid Zentiva 20 mg filmovertrukne tabletter leflunomid
Package leaflet: Information for the user Leflunomide Zentiva 20 mg film-coated tablets leflunomide
Hjerte Almindelig:
Common:
Indlægsseddel: Information til brugeren Leflunomid Zentiva 10 mg filmovertrukne tabletter leflunomid
Package leaflet: Information for the user Leflunomide Zentiva 10 mg film-coated tablets leflunomide
Da det ikke kan udelukkes, at Leflunomid Zentiva findes i sæden, skal der bruges pålidelige prævention under behandlingen med Leflunomid Zentiva.
- if you are male and wish to father a child. As it can not be excluded that Leflunomide Zentiva passes into semen, reliable contraception should be used during treatment with Leflunomide Zentiva.
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Øvrige indholdsstoffer: Majsstivelse, povidon (E1201), crospovidon (E1202), kolloid vandfri silica, magnesiumstearat (E470b) og lactosemonohydrat i tabletkernen, såvel som talcum (E553b), hypromellose (E464), titaniumoxid (E171) og macrogol 8000 i filmovertrækningen.
- The other ingredients are: maize starch, povidone (E1201), crospovidone (E1202), silica colloidal anhydrous, magnesium stearate (E470b), and lactose monohydrate in the tablet core, as well as talc (E553b), hypromellose (E464), titanium dioxide (E171), and macrogol 8000 in the film-coating.
Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer)
Common side effects (may affect up to 1 in 10 people)
Øvrige indholdsstoffer: Majsstivelse, povidon (E1201), crospovidon (E1202), talkum, kolloid vandfri silica, magnesiumstearat (E470b) og lactosemonohydrat i tabletkernen, såvel som talcum (E553b), hypromellose (E464), titaniumoxid (E171) og macrogol 8000 i filmovertrækningen.
- The other ingredients are: maize starch, povidone (E1201), crospovidone (E1202), talc (E553b), silica colloidal anhydrous, magnesium stearate (E470b), and lactose monohydrate in the tablet core, as well as talc (E553b), hypromellose (E464), titanium dioxide (E171), and macrogol 8000 in the film-coating.
Ikke almindelige bivirkninger (kan påvirke op til 1 ud af 100 personer)
Uncommon side effects (may affect up to 1 in 100 people)
EU/1/09/604/005 30 tabletter EU/1/09/604/006 50 tabletter EU/1/09/604/007 100 tabletter
EU/1/09/604/005 30 tablets EU/1/09/604/006 50 tablets EU/1/09/604/007 100 tablets
Der findes pakninger med 30, 50 og 100 tabletter Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Packs of 30, 50 and 100 tablets are available.
Hver tablet indeholder 20 mg leflunomid.
Each tablet contains 20 mg leflunomide.
- hvis du nogensinde har haft en allergisk reaktion over for leflonumid (specielt en alvorlig hudreaktion, ofte ledsaget af feber, ledsmerter, røde pletter på huden eller blærer, f.eks. Stevens
- if you have ever had an allergic reaction to leflunomide (especially a serious skin reaction,
Hver filmovertrukket tablet indeholder 20 mg leflunomid.
Each film-coated tablet contains 20 mg leflunomide.
Hvis du har taget for meget Leflunomid Zentiva
If you take more Leflunomide Zentiva than you should
Hver tablet indeholder 10 mg leflunomid.
Each tablet contains 10 mg leflunomide.
Hver tablet indeholder 100 mg af leflunomid.
Each tablet contains 100 mg of leflunomide.
Leflunomid Zentiva 100 mg filmovertrukne tabletter leflunomid
Leflunomide Zentiva 100 mg film-coated tablets leflunomide
Leflunomid Zentiva 20 mg filmovertrukne tabletter leflunomid
Leflunomide Zentiva 20 mg film-coated tablets leflunomide
Hver filmovertrukket tablet indeholder 100 mg leflunomid.
Each film-coated tablet contains 100 mg leflunomide.
Da eventuelle leverskader forvoldt af alkohol kan forværres af behandling med Leflunomid Zentiva, anbefales det ikke at drikke alkohol under behandling med Leflunomid Zentiva.
It is not recommended to drink alcohol during treatment with Leflunomide Zentiva.
- diarré, - kvalme, opkastning, - inflammation i munden eller mundsår - mavesmerter, - blodprøver, som viser en stigning i nogle resultater for leverfunktion, - øget hårtab, - eksem, tør hud, udslæt, kløe, - seneskedebetændelse (smerte forårsaget af en inflammation i den hinde der omgiver senerne,
- colitis, - diarrhoea, - nausea, vomiting, - inflammation of the mouth or mouth ulcers, - abdominal pain, - an increase in some liver test results, - increased hair loss, - eczema, dry skin, rash, itching, - tendonitis (pain caused by inflammation in the membrane surrounding the tendons usually in the feet or hands), - an increase of certain enzymes in the blood (creatine phosphokinase), - problems in the nerves of the arms or legs (peripheral neuropathy).
Hver filmovertrukket tablet indeholder 10 mg leflunomid.
Each film-coated tablet contains 10 mg leflunomide.
Leflunomid Zentiva 10 mg filmovertrukne tabletter leflunomid
Leflunomide Zentiva 10 mg film-coated tablets leflunomide
Nedsat nyrefunktion
renal failure
Leflunomid Zentiva 20 mg filmovertrukket tablet
Leflunomide Zentiva 20 mg film-coated tablets
EU/1/09/604/008 30 tabletter EU/1/09/604/009 100 tabletter
EU/1/09/604/008 30 tablets EU/1/09/604/009 100 tablets
En filmovertrukken tablet indeholder 100 mg leflunomid.
One film-coated tablet contains 100 mg of leflunomide.
- Øvrige indholdsstoffer: Majsstivelse, povidon (E1201), crospovidon (E1202), kolloid vandfri silica, magnesiumstearat (E470b) og lactosemonohydrat i tabletkernen, såvel som talcum (E553b), hypromellose (E464), titaniumoxid (E171), macrogol 8000 og gul jernoxid (E172) i filmovertrækningen.
One film-coated tablet contains 20 mg of leflunomide - The other ingredients are: maize starch, povidone (E1201), crospovidone (E1202), silica colloidal anhydrous, magnesium stearate (E470b), and lactose monohydrate in the tablet core, as well as talc (E553b), hypromellose (E464), titanium dioxide (E171), macrogol 8000 and yellow ferric oxide (E172) in the film-coating.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON, TABLETGLAS
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER PACKAGING/BOTTLE PACK
EU/1/09/604/001 30 tabletter EU/1/09/604/002 100 tabletter
EU/1/09/604/001 30 tablets EU/1/09/604/002 100 tablets
En filmovertrukken tablet indeholder 10 mg leflunomid.
One film-coated tablet contains 10 mg of leflunomide.
• Informationsfolder til læger
• Periodic Safety Update Reports
Maksimale plasmakoncentrationer kan indtræde mellem 1-24 timer efter indgift af enkeltdosis.
The time to peak plasma concentrations of A771726 is very variable; peak plasma levels can occur between 1 hour and 24 hours after single administration.
EU/1/09/604/003 30 tabletter EU/1/09/604/004 100 tabletter
EU/1/09/604/003 30 tablets EU/1/09/604/004 100 tablets
Leflunomid Zentiva 100 mg filmovertrukket tablet
Leflunomide Zentiva 100 mg film-coated tablets
Bivirkninger
Possible side effects
Leflunomid Zentiva 10 mg filmovertrukket tablet
Leflunomide Zentiva 10 mg film-coated tablets
- hoste eller åndedrætsproblemer, da disse kan være tegn på lungeproblemer (interstitiel lungesygdom eller pulmonal hypertension) - usædvanlig prikken, svaghed eller smerte i dine hænder eller fødder, da dette kan være tegn på problemer med dine nerver (perifer neuropati).
Tell your doctor immediately if you experience: - pale skin, tiredness, or bruising, as these may indicate blood disorders caused by an imbalance in the different types of blood cells which make up blood, - tiredness, abdominal pain, or jaundice (yellow discolouration of the eyes or skin), as these may indicate serious conditions such as liver failure, which may be fatal, - any symptoms of an infection such as fever, sore throat or cough, as this medicine may increase the chance of a severe infection which may be life-threatening, - cough or breathing problems as these may indicate problems of the lung (interstitial lung disease or pulmonary hypertension), - unusual tingling, weakness or pain in your hands or feet as these may indicate problems with your nerves (peripheral neuropathy).
Knogler, led, muskler og bindevæv Almindelig:
Musculoskeletal and connective tissue disorders Common:
MÆRKNING DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE ETIKET, TABLETGLAS
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL
A771726 var den eneste radioaktivt mærkede metabolit, som blev genfundet i plasma.
The only plasma-radiolabelled metabolite detected was A771726.
- træthed, mavesmerter, eller gulsot (gul misfarvning af øjne og hud), da disse kan være tegn på alvorlige problemer, såsom leversvigt, der kan være dødeligt.
severe liver injury such as hepatic failure and acute hepatic necrosis that may be fatal Skin and subcutaneous tissue disorders
Povidon (E 1201) Crospovidon, (E 1202) Talcum (E553b) Kolloid vandfri silica Magnesiumstearat (E 470b) Lactosemonohydrat
Crospovidone (E1202) Talc (E553b)
Dette sammendrag blev sidst ajourført i 10-2009.
This summary was last updated in 10-2009.
Det må ikke anvendes hos patienter med ukontrolleret hypertension.
It must not be used in patients with uncontrolled hypertension.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Biopoin til CT Arzneimittel GmbH den 23. oktober 2009.
The European Commission granted a marketing authorisation valid throughout the European Union for Biopoin to CT Arzneimittel GmbH on 23 October 2009.
Patienter med kræft skal fortsætte med at modtage behandling i op til fire uger, efter at de holder op med at få kemoterapi.
Patients with cancer should continue to receive treatment for up to four weeks after they stop receiving chemotherapy.
Virkningerne af Biopoin blev først afprøvet i forsøgsmodeller, inden de blev undersøgt hos mennesker.
The effects of Biopoin were first tested in experimental models before being studied in humans.
På grund af risikoen for forhøjet blodtryk bør man være særligt opmærksom på at monitorere og kontrollere patientens blodtryk for at undgå komplikationer såsom hypertensiv krise.
Because of the risk of high blood pressure, special care should be taken to monitor and control the patient's blood pressure to avoid complications such as a hypertensive crisis.
Andre oplysninger om Biopoin:
Other information about Biopoin:
Hvis du ønsker yderligere oplysninger om baggrunden for CHMP's anbefalinger, kan du læse den faglige drøftelse (også en del af denne EPAR).
If you want more information on the basis for the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Den anbefalede startdosis er 20.000 IE en gang om ugen for alle patienter uanset deres kropsvægt.
The initial recommended dose is 20,000 IU once a week for all patients irrespective of their body weight.
Hos patienter med kræft skal injektionerne gives under huden.
For patients with cancer, injections should be given under the skin.
Det fremstilles ved hjælp af en metode, der kaldes "rekombinant DNA-teknologi", dvs. det fremstilles af en celle, som har modtaget et gen (DNA), der sætter den i stand til at danne epoetin theta.
It is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce epoetin theta.
Det fås i fyldte injektionssprøjter, som indeholder mellem 1.000 og 30.000 internationale enheder (IE) af det aktive stof, epoetin theta.
It is available in pre-filled syringes containing between 1,000 and 30,000 international units (IU) of the active substance, epoetin theta.
Den fuldstændige EPAR for Biopoin findes her.
The full EPAR for Biopoin can be found here.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Biopoin.
The Committee recommended that Biopoin be given marketing authorisation.
Denne dosis kan fordobles efter fire uger, hvis hæmoglobinniveauet ikke er steget med mindst 1 g/dl, og den kan om nødvendigt øges yderligere til 60.000 IE efter fire uger mere.
This dose may be doubled after four weeks if the haemoglobin has not increased by at least 1 g/dl and can, if needed, be increased further to 60,000 IU after four additional weeks.
Disse doser kan fordobles efter fire uger, hvis der ikke opnås en tilstrækkelig forbedring, og de kan øges yderligere med en fjerdedel af den foregående dosis med månedlige intervaller, indtil det rette hæmoglobinniveau (det protein, der findes i de røde blodlegemer, som transporterer ilt rundt i kroppen) er opnået.
These doses may be doubled after four weeks if the improvement is not enough and may be increased further at monthly intervals by a quarter of the previous dose until the right level of haemoglobin (the protein found in red blood cells that carries oxygen around the body) is achieved.
Erythropoietin dannes i nyrerne.
Erythropoietin is produced by the kidneys.
Patienter, der får Biopoin som injektion under huden, kan injicere sig selv, når de har fået tilstrækkelig undervisning heri.
Patients who receive Biopoin by injection under the skin may inject themselves once they have been trained appropriately.
Når anæmien er blevet korrigeret, skal dosis i "vedligeholdelsesfasen" justeres, så man bevarer det rette hæmoglobinniveau.
When the anaemia has been corrected, the dose in the ‘maintenance phase' should be adjusted to maintain the right level of haemoglobin.
Hos patienter, der får kemoterapi eller har nyreproblemer, kan anæmi opstå som følge af mangel på erythropoietin, eller fordi kroppen ikke reagerer tilstrækkeligt på det erythropoietin, den danner naturligt.
In patients receiving chemotherapy or with kidney problems, anaemia can be caused by a lack of erythropoietin, or by the body not responding enough to the erythropoietin it has naturally.